Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473937 · ClinicalTrials.gov registry record · NA
Radiation Post-CAR T in Refractory Lymphoma
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT04473937: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT04473937 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04473937, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).
Interventions
- RADIATION Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2023-07-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04473937
The ClinicalTrials.gov registry entry for NCT04473937 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiotherapy is the first listed.
NCT04473937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04473937 about?
NCT04473937 is a clinical study titled "Radiation Post-CAR T in Refractory Lymphoma". This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).
What is the current status of trial NCT04473937?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2021-01-05. Estimated completion is 2023-07-03.
What interventions are being tested in trial NCT04473937?
The interventions under investigation include: Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT04473937?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.